Jin Weijun, Marchadier Dawn, Rader Daniel J
University of Pennsylvania School of Medicine, 654 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104, USA.
Trends Endocrinol Metab. 2002 May-Jun;13(4):174-8. doi: 10.1016/s1043-2760(02)00589-1.
Plasma levels of high-density lipoprotein (HDL) cholesterol are strongly inversely associated with atherosclerotic cardiovascular disease, and overexpression of HDL proteins, such as apolipoprotein A-I in animals, reduces progression and even induces regression of atherosclerosis. Therefore, HDL metabolism is recognized as a potential target for therapeutic intervention of atherosclerotic vascular diseases. The antiatherogenic properties of HDL include promotion of cellular cholesterol efflux and reverse cholesterol transport, as well as antioxidant, anti-inflammatory and anticoagulant properties. The molecular regulation of HDL metabolism is not fully understood, but it is influenced by several extracellular lipases. Here, we focus on new developments and insights into the role of secreted lipases on HDL metabolism and their relationship to atherosclerosis.
血浆高密度脂蛋白（HDL）胆固醇水平与动脉粥样硬化性心血管疾病呈强烈负相关，在动物中过表达HDL蛋白，如载脂蛋白A-I，可减缓动脉粥样硬化进展，甚至使其消退。因此，HDL代谢被认为是动脉粥样硬化性血管疾病治疗干预的一个潜在靶点。HDL的抗动脉粥样硬化特性包括促进细胞胆固醇外流和逆向胆固醇转运，以及抗氧化、抗炎和抗凝特性。HDL代谢的分子调控尚未完全明确，但受到几种细胞外脂肪酶的影响。在此，我们重点关注分泌型脂肪酶在HDL代谢中的作用的新进展和新见解，以及它们与动脉粥样硬化的关系。
